ID   A4_RAT                  Reviewed;         770 AA.
AC   P08592; Q547B7;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 2.
DT   02-OCT-2024, entry version 253.
DE   RecName: Full=Amyloid-beta precursor protein {ECO:0000312|RGD:2139};
DE   AltName: Full=ABPP;
DE            Short=APP;
DE   AltName: Full=Alzheimer disease amyloid A4 protein homolog;
DE   AltName: Full=Alzheimer disease amyloid protein;
DE   AltName: Full=Amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Amyloid-beta (A4) precursor protein {ECO:0000312|RGD:2139};
DE   AltName: Full=Amyloid-beta A4 protein {ECO:0000312|RGD:2139};
DE   AltName: Full=Amyloidogenic glycoprotein;
DE            Short=AG;
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha;
DE              Short=S-APP-alpha;
DE   Contains:
DE     RecName: Full=Soluble APP-beta;
DE              Short=S-APP-beta;
DE   Contains:
DE     RecName: Full=C99;
DE     AltName: Full=Beta-secretase C-terminal fragment;
DE              Short=Beta-CTF;
DE   Contains:
DE     RecName: Full=Amyloid-beta protein 42;
DE              Short=Abeta42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Amyloid-beta protein 40;
DE              Short=Abeta40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE     AltName: Full=Alpha-secretase C-terminal fragment;
DE              Short=Alpha-CTF;
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=App {ECO:0000312|RGD:2139};
GN   Synonyms=A4 {ECO:0000250|UniProtKB:P05067},
GN   AD1 {ECO:0000250|UniProtKB:P05067};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=2900758; DOI=10.1002/j.1460-2075.1988.tb02952.x;
RA   Shivers B.D., Hilbich C., Multhaup G., Salbaum J.M., Beyreuther K.,
RA   Seeburg P.H.;
RT   "Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat
RT   brain suggests a role in cell contact.";
RL   EMBO J. 7:1365-1370(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP770).
RA   Feng J., Song S., Zheng J.;
RT   "A new beta amyloid precursor protein cDNA found in Rat6 embryo
RT   fibroblasts.";
RL   Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   PROTEIN SEQUENCE OF 18-44.
RX   PubMed=2968652; DOI=10.1126/science.2968652;
RA   Schubert D., Schroeder R., LaCorbiere M., Saitoh T., Cole G.;
RT   "Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan
RT   core protein.";
RL   Science 241:223-226(1988).
RN   [4]
RP   PROTEIN SEQUENCE OF 18-32.
RX   PubMed=1673681; DOI=10.1016/s0021-9258(18)92997-2;
RA   Potempska A., Styles J., Mehta P., Kim K.S., Miller D.L.;
RT   "Purification and tissue level of the beta-amyloid peptide precursor of rat
RT   brain.";
RL   J. Biol. Chem. 266:8464-8469(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 289-364.
RC   TISSUE=Liver;
RX   PubMed=2648331; DOI=10.1093/nar/17.5.2130;
RA   Kang J., Mueller-Hill B.;
RT   "The sequence of the two extra exons in rat preA4.";
RL   Nucleic Acids Res. 17:2130-2130(1989).
RN   [6]
RP   PROTEIN SEQUENCE OF 720-730, AND MASS SPECTROMETRY.
RX   PubMed=11483588; DOI=10.1074/jbc.c100357200;
RA   Gu Y., Misonou H., Sato T., Dohmae N., Takio K., Ihara Y.;
RT   "Distinct intramembrane cleavage of the beta-amyloid precursor protein
RT   family resembling gamma-secretase-like cleavage of Notch.";
RL   J. Biol. Chem. 276:35235-35238(2001).
RN   [7]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8624099; DOI=10.1111/j.1749-6632.1996.tb34433.x;
RA   Sandbrink R., Masters C.L., Beyreuther K.;
RT   "APP gene family. Alternative splicing generates functionally related
RT   isoforms.";
RL   Ann. N. Y. Acad. Sci. 777:281-287(1996).
RN   [8]
RP   TISSUE SPECIFICITY OF APPICAN.
RX   PubMed=7744833; DOI=10.1074/jbc.270.20.11839;
RA   Shioi J., Pangalos M.N., Ripellino J.A., Vassilacopoulou D., Mytilineou C.,
RA   Margolis R.U., Robakis N.K.;
RT   "The Alzheimer amyloid precursor proteoglycan (appican) is present in brain
RT   and is produced by astrocytes but not by neurons in primary neural
RT   cultures.";
RL   J. Biol. Chem. 270:11839-11844(1995).
RN   [9]
RP   TISSUE SPECIFICITY OF ISOFORMS.
RX   PubMed=8996834; DOI=10.1159/000213840;
RA   Sandbrink R., Monning U., Masters C.L., Beyreuther K.;
RT   "Expression of the APP gene family in brain cells, brain development and
RT   aging.";
RL   Gerontology 43:119-131(1997).
RN   [10]
RP   INTERACTION WITH DDB1, AND MUTAGENESIS OF TYR-757; ASN-759 AND TYR-762.
RX   PubMed=9930726; DOI=10.1046/j.1471-4159.1999.0720549.x;
RA   Watanabe T., Sukegawa J., Tomita S., Iijima K., Oguchi S., Suzuki T.,
RA   Nairn A.C., Greengard P.;
RT   "A 127-kDa protein (UV-DDB) binds to the cytoplasmic domain of the
RT   Alzheimer's amyloid precursor protein.";
RL   J. Neurochem. 72:549-556(1999).
RN   [11]
RP   INTERACTION WITH GNAO1, AND MUTAGENESIS OF 732-HIS-HIS-733.
RX   PubMed=10024358; DOI=10.1523/jneurosci.19-05-01717.1999;
RA   Brouillet E., Trembleau A., Galanaud D., Volovitch M., Bouillot C.,
RA   Valenza C., Prochiantz A., Allinquant B.;
RT   "The amyloid precursor protein interacts with Go heterotrimeric protein
RT   within a cell compartment specialized in signal transduction.";
RL   J. Neurosci. 19:1717-1727(1999).
RN   [12]
RP   COPPER-BINDING.
RX   PubMed=7913895; DOI=10.1016/0014-5793(94)00658-x;
RA   Hesse L., Beher D., Masters C.L., Multhaup G.;
RT   "The beta A4 amyloid precursor protein binding to copper.";
RL   FEBS Lett. 349:109-116(1994).
RN   [13]
RP   CHARACTERISTICS OF APPICAN, AND MUTAGENESIS OF SER-656.
RX   PubMed=7737970; DOI=10.1074/jbc.270.18.10388;
RA   Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.;
RT   "The chondroitin sulfate attachment site of appican is formed by splicing
RT   out exon 15 of the amyloid precursor gene.";
RL   J. Biol. Chem. 270:10388-10391(1995).
RN   [14]
RP   AMYLOID-BETA METAL-BINDING.
RX   PubMed=10386999; DOI=10.1021/bi990438f;
RA   Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E.,
RA   Scarpa R.C., Cuajungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E.,
RA   Bush A.I.;
RT   "The A beta peptide of Alzheimer's disease directly produces hydrogen
RT   peroxide through metal ion reduction.";
RL   Biochemistry 38:7609-7616(1999).
RN   [15]
RP   AMYLOID-BETA ZINC-BINDING.
RX   PubMed=10413512; DOI=10.1021/bi990205o;
RA   Liu S.T., Howlett G., Barrow C.J.;
RT   "Histidine-13 is a crucial residue in the zinc ion-induced aggregation of
RT   the A beta peptide of Alzheimer's disease.";
RL   Biochemistry 38:9373-9378(1999).
RN   [16]
RP   IMPORTANCE OF GLY-704 IN FREE RADICAL PROPAGATION, AND MUTAGENESIS OF
RP   GLY-704.
RX   PubMed=11959460; DOI=10.1016/s0925-4439(01)00097-7;
RA   Kanski J., Varadarajan S., Aksenova M., Butterfield D.A.;
RT   "Role of glycine-33 and methionine-35 in Alzheimer's amyloid-beta peptide
RT   1-42-associated oxidative stress and neurotoxicity.";
RL   Biochim. Biophys. Acta 1586:190-198(2002).
RN   [17]
RP   PHOSPHORYLATION AT THR-729; SER-730 AND THR-743.
RX   PubMed=9085254; DOI=10.1007/bf03401803;
RA   Oishi M., Nairn A.C., Czernik A.J., Lim G.S., Isohara T., Gandy S.E.,
RA   Greengard P., Suzuki T.;
RT   "The cytoplasmic domain of Alzheimer's amyloid precursor protein is
RT   phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and
RT   cultured cells.";
RL   Mol. Med. 3:111-123(1997).
RN   [18]
RP   PHOSPHORYLATION AT SER-730.
RX   PubMed=10329382; DOI=10.1006/bbrc.1999.0637;
RA   Isohara T., Horiuchi A., Watanabe T., Ando K., Czernik A.J., Uno I.,
RA   Greengard P., Nairn A.C., Suzuki T.;
RT   "Phosphorylation of the cytoplasmic domain of Alzheimer's beta-amyloid
RT   precursor protein at Ser655 by a novel protein kinase.";
RL   Biochem. Biophys. Res. Commun. 258:300-305(1999).
RN   [19]
RP   PHOSPHORYLATION, INDUCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   THR-743.
RX   PubMed=10341243; DOI=10.1523/jneurosci.19-11-04421.1999;
RA   Ando K., Oishi M., Takeda S., Iijima K., Isohara T., Nairn A.C., Kirino Y.,
RA   Greengard P., Suzuki T.;
RT   "Role of phosphorylation of Alzheimer's amyloid precursor protein during
RT   neuronal differentiation.";
RL   J. Neurosci. 19:4421-4427(1999).
RN   [20]
RP   PHOSPHORYLATION AT THR-743.
RX   PubMed=10936190; DOI=10.1046/j.1471-4159.2000.0751085.x;
RA   Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S., Greengard P.,
RA   Kirino Y., Nairn A.C., Suzuki T.;
RT   "Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor
RT   protein by cyclin-dependent kinase 5.";
RL   J. Neurochem. 75:1085-1091(2000).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-441, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [22]
RP   INTERACTION WITH KIF5B, AND TISSUE SPECIFICITY.
RX   PubMed=23011729; DOI=10.1088/1478-3975/9/5/055005;
RA   Seamster P.E., Loewenberg M., Pascal J., Chauviere A., Gonzales A.,
RA   Cristini V., Bearer E.L.;
RT   "Quantitative measurements and modeling of cargo-motor interactions during
RT   fast transport in the living axon.";
RL   Phys. Biol. 9:055005-055005(2012).
RN   [23]
RP   UBIQUITINATION AT LYS-763, AND MUTAGENESIS OF LYS-763.
RX   PubMed=22847417; DOI=10.1073/pnas.1206786109;
RA   El Ayadi A., Stieren E.S., Barral J.M., Boehning D.;
RT   "Ubiquilin-1 regulates amyloid precursor protein maturation and degradation
RT   by stimulating K63-linked polyubiquitination of lysine 688.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:13416-13421(2012).
RN   [24]
RP   PROTEOLYTIC PROCESSING, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=26479776; DOI=10.1021/acs.jproteome.5b00820;
RA   Tsuchiya T., Osaki T., Minamino N., Sasaki K.;
RT   "Peptidomics for studying limited proteolysis.";
RL   J. Proteome Res. 14:4921-4931(2015).
RN   [25]
RP   STRUCTURE OF CARBOHYDRATE IN APPICAN, AND GLYCOSYLATION.
RX   PubMed=11479316; DOI=10.1074/jbc.m105818200;
RA   Tsuchida K., Shioi J., Yamada S., Boghosian G., Wu A., Cai H., Sugahara K.,
RA   Robakis N.K.;
RT   "Appican, the proteoglycan form of the amyloid precursor protein, contains
RT   chondroitin sulfate E in the repeating disaccharide region and 4-O-sulfated
RT   galactose in the linkage region.";
RL   J. Biol. Chem. 276:37155-37160(2001).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to neurite
CC       growth, neuronal adhesion and axonogenesis. Interaction between APP
CC       molecules on neighboring cells promotes synaptogenesis. Involved in
CC       cell mobility and transcription regulation through protein-protein
CC       interactions (By similarity). Can promote transcription activation
CC       through binding to APBB1-KAT5 and inhibit Notch signaling through
CC       interaction with Numb (By similarity). Couples to apoptosis-inducing
CC       pathways such as those mediated by G(o) and JIP. Inhibits G(o)-alpha
CC       ATPase activity. Acts as a kinesin I membrane receptor, mediating the
CC       axonal transport of beta-secretase and presenilin 1 (By similarity). By
CC       acting as a kinesin I membrane receptor, plays a role in axonal
CC       anterograde transport of cargo towards synapses in axons (By
CC       similarity). May be involved in copper homeostasis/oxidative stress
CC       through copper ion reduction. Can regulate neurite outgrowth through
CC       binding to components of the extracellular matrix such as heparin and
CC       collagen I and IV (By similarity). The splice isoforms that contain the
CC       BPTI domain possess protease inhibitor activity. Induces a AGER-
CC       dependent pathway that involves activation of p38 MAPK, resulting in
CC       internalization of amyloid-beta peptide and leading to mitochondrial
CC       dysfunction in cultured mitochondrial dysfunction in cultured cortical
CC       neurons. Provides Cu(2+) ions for GPC1 which are required for release
CC       of nitric oxide (NO) and subsequent degradation of the heparan sulfate
CC       chains on GPC1 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P05067}.
CC   -!- FUNCTION: Amyloid-beta peptides are lipophilic metal chelators with
CC       metal-reducing activity. Binds transient metals such as copper, zinc
CC       and iron. Rat and mouse amyloid-beta peptides bind only weakly
CC       transient metals and have little reducing activity due to substitutions
CC       of transient metal chelating residues. Amyloid-beta protein 42 may
CC       activate mononuclear phagocytes in the brain and elicits inflammatory
CC       responses. Promotes both tau aggregation and TPK II-mediated
CC       phosphorylation. Also binds GPC1 in lipid rafts (By similarity).
CC       {ECO:0000250}.
CC   -!- FUNCTION: Appicans elicit adhesion of neural cells to the extracellular
CC       matrix and may regulate neurite outgrowth in the brain.
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal apoptosis.
CC       {ECO:0000250}.
CC   -!- FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and
CC       degeneration of both neuronal cell bodies (via caspase-3) and axons
CC       (via caspase-6). {ECO:0000250}.
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA family,
CC       MAPK8IP1, SHC1 and NUMB and DAB1 (By similarity). Binding to DAB1
CC       inhibits its serine phosphorylation (By similarity). Interacts (via
CC       NPXY motif) with DAB2 (via PID domain); the interaction is impaired by
CC       tyrosine phosphorylation of the NPXY motif. Also interacts with GPCR-
CC       like protein BPP, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via
CC       BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains (By
CC       similarity). Associates with microtubules in the presence of ATP and in
CC       a kinesin-dependent manner (By similarity). Interacts, through a C-
CC       terminal domain, with GNAO1. Amyloid-beta protein 42 binds CHRNA7 in
CC       hippocampal neurons (By similarity). Amyloid-beta associates with HADH2
CC       (By similarity). Interacts with CPEB1, ANKS1B, TNFRSF21 and AGER (By
CC       similarity). Interacts with ITM2B. Interacts with ITM2C. Interacts with
CC       IDE. Can form homodimers; dimerization is enhanced in the presence of
CC       Cu(2+) ions. Can form homodimers; this is promoted by heparin binding
CC       (By similarity). Amyloid-beta protein 40 interacts with S100A9 (By
CC       similarity). CTF-alpha product of APP interacts with GSAP (By
CC       similarity). Isoform APP695 interacts with SORL1 (via N-terminal
CC       ectodomain); this interaction retains APP in the trans-Golgi network
CC       and reduces processing into soluble APP-alpha and amyloid-beta peptides
CC       (By similarity). The C99 fragment also interacts with SORL1 (By
CC       similarity). Isoform APP751 interacts with SORL1 (By similarity).
CC       Isoform APP770 interacts with SORL1 (By similarity). Interacts with
CC       PLD3 (By similarity). Interacts with VDAC1 (By similarity). Interacts
CC       with NSG1; could regulate APP processing (By similarity). Amyloid-beta
CC       protein 42 interacts with FPR2 (By similarity). Interacts with SYT7 (By
CC       similarity). Interacts (via transmembrane region) with PSEN1; the
CC       interaction is direct (By similarity). Interacts with LRRK2 (By
CC       similarity). Interacts (via cytoplasmic domain) with KIF5B
CC       (PubMed:23011729). Interacts (via C-terminus) with APBB2/FE65L1 (via C-
CC       terminus) (By similarity). Interacts (via intracellular domain) with
CC       APBB3 (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P05067,
CC       ECO:0000250|UniProtKB:P12023, ECO:0000269|PubMed:23011729}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P05067};
CC       Single-pass type I membrane protein {ECO:0000250|UniProtKB:P05067}.
CC       Membrane {ECO:0000250|UniProtKB:P05067}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P05067}. Perikaryon
CC       {ECO:0000269|PubMed:10341243}. Cell projection, growth cone
CC       {ECO:0000269|PubMed:10341243}. Membrane, clathrin-coated pit
CC       {ECO:0000250|UniProtKB:P05067}. Early endosome
CC       {ECO:0000250|UniProtKB:P05067}. Cytoplasmic vesicle
CC       {ECO:0000250|UniProtKB:P05067}. Note=Cell surface protein that rapidly
CC       becomes internalized via clathrin-coated pits. Only a minor proportion
CC       is present at the cell membrane; most of the protein is present in
CC       intracellular vesicles. During maturation, the immature APP (N-
CC       glycosylated in the endoplasmic reticulum) moves to the Golgi complex
CC       where complete maturation occurs (O-glycosylated and sulfated). After
CC       alpha-secretase cleavage, soluble APP is released into the
CC       extracellular space and the C-terminal is internalized to endosomes and
CC       lysosomes. Some APP accumulates in secretory transport vesicles leaving
CC       the late Golgi compartment and returns to the cell surface. APP sorts
CC       to the basolateral surface in epithelial cells (By similarity). During
CC       neuronal differentiation, the Thr-742 phosphorylated form is located
CC       mainly in growth cones, moderately in neurites and sparingly in the
CC       cell body (PubMed:10341243). Casein kinase phosphorylation can occur
CC       either at the cell surface or within a post-Golgi compartment.
CC       Associates with GPC1 in perinuclear compartments. Colocalizes with
CC       SORL1 in a vesicular pattern in cytoplasm and perinuclear regions (By
CC       similarity). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000269|PubMed:10341243}.
CC   -!- SUBCELLULAR LOCATION: [C83]: Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P05067}. Golgi apparatus
CC       {ECO:0000250|UniProtKB:P05067}. Early endosome
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: [C99]: Early endosome
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: [Amyloid-beta protein 42]: Cell surface.
CC       Note=Associates with FPR2 at the cell surface and the complex is then
CC       rapidly internalized. {ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: [Gamma-secretase C-terminal fragment 59]:
CC       Nucleus. Cytoplasm. Note=Located to both the cytoplasm and nuclei of
CC       neurons. It can be translocated to the nucleus through association with
CC       APBB1 (Fe65) (By similarity). In dopaminergic neurons, the
CC       phosphorylated Thr-743 form is localized to the nucleus (By
CC       similarity). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000250|UniProtKB:P12023}.
CC   -!- SUBCELLULAR LOCATION: [Soluble APP-beta]: Secreted
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=APP770;
CC         IsoId=P08592-1; Sequence=Displayed;
CC       Name=APP695;
CC         IsoId=P08592-2; Sequence=VSP_000015, VSP_000016;
CC       Name=L-APP677;
CC         IsoId=P08592-3; Sequence=Not described;
CC       Name=L-APP696;
CC         IsoId=P08592-4; Sequence=Not described;
CC       Name=APP714;
CC         IsoId=P08592-5; Sequence=Not described;
CC       Name=L-APP733;
CC         IsoId=P08592-6; Sequence=Not described;
CC       Name=APP751;
CC         IsoId=P08592-7; Sequence=Not described;
CC       Name=L-APP752;
CC         IsoId=P08592-8; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Expressed in the brain (PubMed:23011729). In the
CC       brain, non-L-APP isoforms are expressed in neurons, isoform APP695
CC       being the predominant form. In astrocytes and microglial cells, almost
CC       50% is L-isoform (appican). {ECO:0000269|PubMed:23011729,
CC       ECO:0000269|PubMed:7744833, ECO:0000269|PubMed:8996834}.
CC   -!- DEVELOPMENTAL STAGE: From 6 days to 7 months, levels of KPI-containing
CC       isoforms increase in the brain cortex and hippocampus. Levels of L-APP
CC       increase in all brain regions during the same period, but levels are
CC       low compared to non-L-APP isoforms.
CC   -!- INDUCTION: Phosphorylation of mature, glycosylated APP occurs 48-72
CC       hours after treatment of neuronal cells with nerve growth factor which
CC       correlates with the timing of neurite outgrowth.
CC       {ECO:0000269|PubMed:10341243}.
CC   -!- DOMAIN: The transmembrane helix undergoes a conformation change and
CC       unravels partially when bound to PSEN1, facilitating cleavage by PSEN1.
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for sorting
CC       of membrane proteins to the basolateral surface of epithelial cells.
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The GFLD subdomain binds Cu(2+) ions; this promotes
CC       homodimerization. {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-phosphorylated
CC       proteins is required for the specific binding of the PID domain.
CC       However, additional amino acids either N- or C-terminal to the NPXY
CC       motif are often required for complete interaction. The PID domain-
CC       containing proteins which bind APP require the YENPTY motif for full
CC       interaction. These interactions are independent of phosphorylation on
CC       the terminal tyrosine residue. The YENPXY site is also involved in
CC       clathrin-mediated endocytosis. {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The C-terminal region can bind zinc ions; this favors
CC       dimerization and formation of higher oligomers.
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The OX-2 motif shows some similarity to a region in the N-
CC       terminus of CD200/MOX2. {ECO:0000250|UniProtKB:P05067}.
CC   -!- PTM: Proteolytically processed under normal cellular conditions.
CC       Cleavage either by alpha-secretase, beta-secretase or theta-secretase
CC       leads to generation and extracellular release of soluble APP peptides,
CC       S-APP-alpha and S-APP-beta, and the retention of corresponding
CC       membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent
CC       processing of C80 and C83 by gamma-secretase yields P3 peptides. This
CC       is the major secretory pathway and is non-amyloidogenic. Alternatively,
CC       presenilin/nicastrin-mediated gamma-secretase processing of C99
CC       releases the amyloid-beta proteins, amyloid-beta protein 40 and
CC       amyloid-beta protein 42, major components of amyloid plaques, and the
CC       cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-
CC       CTF(59). PSEN1 cleavage is more efficient with C83 than with C99 as
CC       substrate (in vitro). Amyloid-beta protein 40 and Amyloid-beta protein
CC       42 are cleaved by ACE. Many other minor amyloid-beta peptides, amyloid-
CC       beta 1-X peptides, are found in cerebral spinal fluid (CSF) including
CC       the amyloid-beta X-15 peptides, produced from the cleavage by alpha-
CC       secretase. {ECO:0000250|UniProtKB:P05067}.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal apoptosis.
CC       Cleavage at Asp-739 by either caspase-3, -8 or -9 results in the
CC       production of the neurotoxic C31 peptide and the increased production
CC       of amyloid-beta peptides. {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000250|UniProtKB:P05067}.
CC   -!- PTM: O-glycosylated. O-linkage of chondroitin sulfate to the L-APP
CC       isoforms produces the APP proteoglycan core proteins, the appicans. The
CC       chondroitin sulfate chain of appicans contains 4-O-sulfated galactose
CC       in the linkage region and chondroitin sulfate E in the repeated
CC       disaccharide region. {ECO:0000269|PubMed:11479316}.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific (PubMed:10329382, PubMed:10341243,
CC       PubMed:9085254). Phosphorylation can affect APP processing, neuronal
CC       differentiation and interaction with other proteins (PubMed:10341243).
CC       Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10,
CC       in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with
CC       maximal levels at the G2/M phase and, in vitro, by GSK-3-beta
CC       (PubMed:10936190). The Thr-743 phosphorylated form causes a
CC       conformational change which reduces binding of Fe65 family members (By
CC       similarity). In dopaminergic (DA) neurons, phosphorylation on Thr-743
CC       by LRKK2 promotes the production and the nuclear translocation of the
CC       APP intracellular domain (AICD) which induces DA neuron apoptosis (By
CC       similarity). Phosphorylation on Tyr-757 is required for SHC binding.
CC       Phosphorylated in the extracellular domain by casein kinases on both
CC       soluble and membrane-bound APP (By similarity). This phosphorylation is
CC       inhibited by heparin (By similarity). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000269|PubMed:10329382, ECO:0000269|PubMed:10341243,
CC       ECO:0000269|PubMed:10936190, ECO:0000269|PubMed:9085254}.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation of a
CC       disulfide bond. {ECO:0000250}.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface APP by
CC       beta-secretase to release sAPP-beta which is further cleaved to release
CC       an N-terminal fragment of APP (N-APP). {ECO:0000250}.
CC   -!- PTM: Amyloid-beta peptides are degraded by IDE.
CC       {ECO:0000250|UniProtKB:P12023}.
CC   -!- PTM: Sulfated on tyrosine residues. {ECO:0000250|UniProtKB:P05067}.
CC   -!- MASS SPECTROMETRY: [Gamma-secretase C-terminal fragment 50]:
CC       Mass=5911.3; Method=MALDI; Evidence={ECO:0000269|PubMed:11483588};
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and zinc,
CC       can induce histidine-bridging between amyloid-beta molecules resulting
CC       in amyloid-beta-metal aggregates. Rat and mouse amyloid-beta peptides
CC       have an arginine residue substituted for the bridging histidine residue
CC       and are thus less capable of forming amyloid aggregates. Extracellular
CC       zinc-binding increases binding of heparin to APP and inhibits collagen-
CC       binding (By similarity). {ECO:0000250|UniProtKB:P05067, ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform L-APP677]: L-isoforms are referred to as
CC       appicans. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform L-APP696]: L-isoforms are referred to as
CC       appicans. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform L-APP733]: L-isoforms are referred to as
CC       appicans. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform L-APP752]: L-isoforms are referred to as
CC       appicans. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the APP family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01217}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X07648; CAA30488.1; -; mRNA.
DR   EMBL; AF513015; AAM90259.1; -; mRNA.
DR   EMBL; X14066; CAA32229.1; -; mRNA.
DR   PIR; S00550; S00550.
DR   PIR; S03607; S03607.
DR   PIR; S23094; S23094.
DR   RefSeq; NP_062161.1; NM_019288.2. [P08592-1]
DR   PDB; 1M7E; X-ray; 2.45 A; D/E/F=755-763.
DR   PDB; 1NMJ; NMR; -; A=672-699.
DR   PDB; 1OQN; X-ray; 2.30 A; C/D=755-763.
DR   PDB; 2LI9; NMR; -; A/B=672-687.
DR   PDBsum; 1M7E; -.
DR   PDBsum; 1NMJ; -.
DR   PDBsum; 1OQN; -.
DR   PDBsum; 2LI9; -.
DR   AlphaFoldDB; P08592; -.
DR   BMRB; P08592; -.
DR   SMR; P08592; -.
DR   BioGRID; 248450; 6.
DR   ComplexPortal; CPX-1108; Amyloid-beta protein 40/42 complex.
DR   ComplexPortal; CPX-1109; Amyloid-beta protein 40 complex.
DR   ComplexPortal; CPX-1110; Amyloid-beta protein 42 complex.
DR   ComplexPortal; CPX-1182; Amyloid-beta protein 40 oligomeric complex.
DR   ComplexPortal; CPX-1183; Amyloid-beta protein 42 oligomeric complex.
DR   ComplexPortal; CPX-1184; Amyloid-beta protein 40/42 oligomeric complex.
DR   DIP; DIP-618N; -.
DR   ELM; P08592; -.
DR   IntAct; P08592; 13.
DR   STRING; 10116.ENSRNOP00000041613; -.
DR   BindingDB; P08592; -.
DR   ChEMBL; CHEMBL3638365; -.
DR   MEROPS; I02.015; -.
DR   TCDB; 1.C.50.1.1; the amyloid Beta-protein peptide (aBetapp) family.
DR   GlyCosmos; P08592; 3 sites, No reported glycans.
DR   GlyGen; P08592; 3 sites.
DR   iPTMnet; P08592; -.
DR   PhosphoSitePlus; P08592; -.
DR   jPOST; P08592; -.
DR   PaxDb; 10116-ENSRNOP00000041613; -.
DR   Ensembl; ENSRNOT00055003610; ENSRNOP00055002711; ENSRNOG00055002269. [P08592-1]
DR   Ensembl; ENSRNOT00060028680; ENSRNOP00060023069; ENSRNOG00060016739. [P08592-1]
DR   Ensembl; ENSRNOT00065009663; ENSRNOP00065006970; ENSRNOG00065006297. [P08592-1]
DR   GeneID; 54226; -.
DR   KEGG; rno:54226; -.
DR   UCSC; RGD:2139; rat. [P08592-1]
DR   AGR; RGD:2139; -.
DR   CTD; 351; -.
DR   RGD; 2139; App.
DR   VEuPathDB; HostDB:ENSRNOG00000006997; -.
DR   eggNOG; KOG3540; Eukaryota.
DR   HOGENOM; CLU_014607_2_1_1; -.
DR   InParanoid; P08592; -.
DR   OrthoDB; 2907766at2759; -.
DR   PhylomeDB; P08592; -.
DR   TreeFam; TF317274; -.
DR   Reactome; R-RNO-114608; Platelet degranulation.
DR   Reactome; R-RNO-3000178; ECM proteoglycans.
DR   Reactome; R-RNO-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-418594; G alpha (i) signalling events.
DR   Reactome; R-RNO-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-RNO-444473; Formyl peptide receptors bind formyl peptides and many other ligands.
DR   Reactome; R-RNO-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-RNO-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-RNO-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-RNO-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-RNO-9609523; Insertion of tail-anchored proteins into the endoplasmic reticulum membrane.
DR   Reactome; R-RNO-9837999; Mitochondrial protein degradation.
DR   EvolutionaryTrace; P08592; -.
DR   PRO; PR:P08592; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Bgee; ENSRNOG00000006997; Expressed in frontal cortex and 19 other cell types or tissues.
DR   ExpressionAtlas; P08592; baseline and differential.
DR   GO; GO:0106003; C:amyloid-beta complex; ISO:RGD.
DR   GO; GO:0045177; C:apical part of cell; ISO:RGD.
DR   GO; GO:0097449; C:astrocyte projection; IDA:RGD.
DR   GO; GO:0030424; C:axon; IDA:AgBase.
DR   GO; GO:0009986; C:cell surface; IDA:AgBase.
DR   GO; GO:0005911; C:cell-cell junction; ISO:RGD.
DR   GO; GO:0035253; C:ciliary rootlet; ISO:RGD.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0030134; C:COPII-coated ER to Golgi transport vesicle; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; ISO:RGD.
DR   GO; GO:0043198; C:dendritic shaft; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; ISO:RGD.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005768; C:endosome; ISO:RGD.
DR   GO; GO:0070381; C:endosome to plasma membrane transport vesicle; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0005798; C:Golgi-associated vesicle; ISS:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IDA:RGD.
DR   GO; GO:1990812; C:growth cone filopodium; IDA:RGD.
DR   GO; GO:1990761; C:growth cone lamellipodium; IDA:RGD.
DR   GO; GO:1990777; C:lipoprotein particle; ISO:RGD.
DR   GO; GO:0005764; C:lysosome; ISO:RGD.
DR   GO; GO:0044304; C:main axon; IDA:RGD.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISO:RGD.
DR   GO; GO:0031594; C:neuromuscular junction; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0098992; C:neuronal dense core vesicle; IDA:SynGO.
DR   GO; GO:0005641; C:nuclear envelope lumen; ISO:RGD.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0048786; C:presynaptic active zone; ISO:RGD.
DR   GO; GO:0043235; C:receptor complex; ISO:RGD.
DR   GO; GO:0055037; C:recycling endosome; ISS:UniProtKB.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:GOC.
DR   GO; GO:0051233; C:spindle midzone; ISO:RGD.
DR   GO; GO:0045202; C:synapse; ISO:RGD.
DR   GO; GO:0008021; C:synaptic vesicle; ISO:RGD.
DR   GO; GO:0043195; C:terminal bouton; HDA:ParkinsonsUK-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0005109; F:frizzled binding; ISO:RGD.
DR   GO; GO:0070851; F:growth factor receptor binding; IPI:RGD.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISO:RGD.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISO:RGD.
DR   GO; GO:0016504; F:peptidase activator activity; IDA:RGD.
DR   GO; GO:0120283; F:protein serine/threonine kinase binding; ISO:RGD.
DR   GO; GO:0051425; F:PTB domain binding; ISO:RGD.
DR   GO; GO:0048018; F:receptor ligand activity; ISO:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; ISO:RGD.
DR   GO; GO:0030546; F:signaling receptor activator activity; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:RGD.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:UniProtKB.
DR   GO; GO:1990000; P:amyloid fibril formation; ISO:RGD.
DR   GO; GO:0061844; P:antimicrobial humoral immune response mediated by antimicrobial peptide; ISO:RGD.
DR   GO; GO:0048143; P:astrocyte activation; ISO:RGD.
DR   GO; GO:0002265; P:astrocyte activation involved in immune response; ISO:RGD.
DR   GO; GO:0008088; P:axo-dendritic transport; ISS:UniProtKB.
DR   GO; GO:0016199; P:axon midline choice point recognition; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; ISO:RGD.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:RGD.
DR   GO; GO:0071280; P:cellular response to copper ion; IEP:RGD.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEP:RGD.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEP:RGD.
DR   GO; GO:0071874; P:cellular response to norepinephrine stimulus; IMP:RGD.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0008203; P:cholesterol metabolic process; ISO:RGD.
DR   GO; GO:0050890; P:cognition; ISS:UniProtKB.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; ISS:UniProtKB.
DR   GO; GO:0180011; P:cytosolic mRNA polyadenylation; ISO:RGD.
DR   GO; GO:0016358; P:dendrite development; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; ISS:UniProtKB.
DR   GO; GO:0030198; P:extracellular matrix organization; ISS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; ISO:RGD.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0045087; P:innate immune response; ISO:RGD.
DR   GO; GO:0006878; P:intracellular copper ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007612; P:learning; ISO:RGD.
DR   GO; GO:0007611; P:learning or memory; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007617; P:mating behavior; ISS:UniProtKB.
DR   GO; GO:0014005; P:microglia development; ISO:RGD.
DR   GO; GO:0001774; P:microglial cell activation; ISO:RGD.
DR   GO; GO:0000278; P:mitotic cell cycle; ISO:RGD.
DR   GO; GO:0098815; P:modulation of excitatory postsynaptic potential; ISO:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; ISO:RGD.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; ISO:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; ISO:RGD.
DR   GO; GO:0070050; P:neuron cellular homeostasis; ISO:RGD.
DR   GO; GO:0030182; P:neuron differentiation; ISO:RGD.
DR   GO; GO:0031175; P:neuron projection development; ISS:UniProtKB.
DR   GO; GO:1990535; P:neuron projection maintenance; ISO:RGD.
DR   GO; GO:0016322; P:neuron remodeling; ISS:UniProtKB.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:1905908; P:positive regulation of amyloid fibril formation; ISO:RGD.
DR   GO; GO:0050850; P:positive regulation of calcium-mediated signaling; ISO:RGD.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISO:RGD.
DR   GO; GO:1904472; P:positive regulation of endothelin production; ISO:RGD.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISO:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISO:RGD.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISO:RGD.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; ISO:RGD.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISO:RGD.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IDA:ARUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:2000406; P:positive regulation of T cell migration; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:1900221; P:regulation of amyloid-beta clearance; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; ISO:RGD.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; ISO:RGD.
DR   GO; GO:1905606; P:regulation of presynapse assembly; ISO:RGD.
DR   GO; GO:0150003; P:regulation of spontaneous synaptic transmission; ISO:RGD.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; ISS:UniProtKB.
DR   GO; GO:0070555; P:response to interleukin-1; IDA:ARUK-UCL.
DR   GO; GO:0010288; P:response to lead ion; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; ISO:RGD.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; ISO:RGD.
DR   GO; GO:0001967; P:suckling behavior; ISO:RGD.
DR   GO; GO:0050808; P:synapse organization; ISO:RGD.
DR   GO; GO:0051124; P:synaptic assembly at neuromuscular junction; ISO:RGD.
DR   GO; GO:0008542; P:visual learning; ISS:UniProtKB.
DR   CDD; cd22607; Kunitz_ABPP-like; 1.
DR   DisProt; DP01887; -.
DR   Gene3D; 6.10.250.1670; -; 1.
DR   Gene3D; 1.20.120.770; Amyloid precursor protein, E2 domain; 1.
DR   Gene3D; 3.30.1490.140; Amyloidogenic glycoprotein, copper-binding domain; 1.
DR   Gene3D; 3.90.570.10; Amyloidogenic glycoprotein, heparin-binding domain; 1.
DR   Gene3D; 4.10.410.10; Pancreatic trypsin inhibitor Kunitz domain; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR036669; Amyloid_Cu-bd_sf.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR036454; Amyloid_glyco_heparin-bd_sf.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR019744; APP_CUBD_CS.
DR   InterPro; IPR036176; E2_sf.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR036880; Kunitz_BPTI_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103; ALZHEIMER'S DISEASE BETA-AMYLOID RELATED; 1.
DR   PANTHER; PTHR23103:SF7; AMYLOID-BETA PRECURSOR PROTEIN; 1.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF56491; A heparin-binding domain; 1.
DR   SUPFAM; SSF89811; Amyloid beta a4 protein copper binding domain (domain 2); 1.
DR   SUPFAM; SSF57362; BPTI-like; 1.
DR   SUPFAM; SSF109843; CAPPD, an extracellular domain of amyloid beta A4 protein; 1.
DR   PROSITE; PS00319; APP_CUBD; 1.
DR   PROSITE; PS51869; APP_E1; 1.
DR   PROSITE; PS51870; APP_E2; 1.
DR   PROSITE; PS00320; APP_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyloid; Apoptosis; Cell adhesion;
KW   Cell membrane; Cell projection; Coated pit; Copper; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disulfide bond;
KW   Endocytosis; Endoplasmic reticulum; Endosome; Glycoprotein;
KW   Golgi apparatus; Heparin-binding; Iron; Isopeptide bond; Membrane;
KW   Metal-binding; Notch signaling pathway; Nucleus; Phosphoprotein;
KW   Protease inhibitor; Proteoglycan; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal; Sulfation; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Zinc.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   CHAIN           18..770
FT                   /note="Amyloid-beta precursor protein"
FT                   /id="PRO_0000000159"
FT   CHAIN           18..687
FT                   /note="Soluble APP-alpha"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000160"
FT   CHAIN           18..671
FT                   /note="Soluble APP-beta"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000000161"
FT   CHAIN           18..286
FT                   /note="N-APP"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000381971"
FT   CHAIN           672..770
FT                   /note="C99"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000000162"
FT   CHAIN           672..713
FT                   /note="Amyloid-beta protein 42"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT                   /id="PRO_0000000163"
FT   CHAIN           672..711
FT                   /note="Amyloid-beta protein 40"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT                   /id="PRO_0000000164"
FT   CHAIN           688..770
FT                   /note="C83"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000165"
FT   PEPTIDE         688..713
FT                   /note="P3(42)"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000166"
FT   PEPTIDE         688..711
FT                   /note="P3(40)"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000167"
FT   CHAIN           691..770
FT                   /note="C80"
FT                   /id="PRO_0000384579"
FT   CHAIN           712..770
FT                   /note="Gamma-secretase C-terminal fragment 59"
FT                   /id="PRO_0000000168"
FT   CHAIN           714..770
FT                   /note="Gamma-secretase C-terminal fragment 57"
FT                   /id="PRO_0000000169"
FT   CHAIN           721..770
FT                   /note="Gamma-secretase C-terminal fragment 50"
FT                   /id="PRO_0000000170"
FT   CHAIN           740..770
FT                   /note="C31"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000171"
FT   TOPO_DOM        18..701
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        702..722
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   TOPO_DOM        723..770
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          28..189
FT                   /note="E1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DOMAIN          291..341
FT                   /note="BPTI/Kunitz inhibitor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   DOMAIN          374..565
FT                   /note="E2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01218"
FT   REGION          28..123
FT                   /note="GFLD subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   REGION          131..189
FT                   /note="CuBD subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   REGION          135..155
FT                   /note="Copper-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          181..188
FT                   /note="Zinc-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          196..283
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          391..423
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          491..522
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          523..540
FT                   /note="Collagen-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   REGION          695..722
FT                   /note="Interaction with PSEN1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   REGION          732..751
FT                   /note="Interaction with G(o)-alpha"
FT   REGION          756..770
FT                   /note="Required for the interaction with KIF5B and for
FT                   anterograde transport in axons"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOTIF           344..365
FT                   /note="OX-2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOTIF           724..734
FT                   /note="Basolateral sorting signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           757..762
FT                   /note="YENPXY motif; contains endocytosis signal"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   COMPBIAS        196..210
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        225..263
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        267..283
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         96..110
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         147
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   BINDING         151
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   BINDING         168
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   BINDING         183
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         186
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         187
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         677
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         677
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         685
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         685
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            170
FT                   /note="Required for Cu(2+) reduction"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   SITE            197..198
FT                   /note="Cleavage; by caspases"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            219..220
FT                   /note="Cleavage; by caspases"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            301..302
FT                   /note="Reactive bond"
FT                   /evidence="ECO:0000250"
FT   SITE            671..672
FT                   /note="Cleavage; by beta-secretase"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            678..679
FT                   /note="Cleavage; by ACE"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            687..688
FT                   /note="Cleavage; by alpha-secretase"
FT                   /evidence="ECO:0000269|PubMed:26479776"
FT   SITE            690..691
FT                   /note="Cleavage; by theta-secretase"
FT                   /evidence="ECO:0000269|PubMed:26479776"
FT   SITE            706
FT                   /note="Susceptible to oxidation"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            711..712
FT                   /note="Cleavage; by gamma-secretase; site 1"
FT                   /evidence="ECO:0000269|PubMed:26479776"
FT   SITE            713..714
FT                   /note="Cleavage; by gamma-secretase; site 2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            720..721
FT                   /note="Cleavage; by gamma-secretase; site 3"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            739..740
FT                   /note="Cleavage; by a caspase"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         198
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         206
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         217
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         262
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         336
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         497
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         729
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:9085254"
FT   MOD_RES         730
FT                   /note="Phosphoserine; by APP-kinase I"
FT                   /evidence="ECO:0000269|PubMed:10329382,
FT                   ECO:0000269|PubMed:9085254"
FT   MOD_RES         743
FT                   /note="Phosphothreonine; by CDK5 and MAPK10"
FT                   /evidence="ECO:0000269|PubMed:10936190,
FT                   ECO:0000269|PubMed:9085254"
FT   MOD_RES         757
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000250|UniProtKB:P12023"
FT   CARBOHYD        542
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        571
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        656
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine; in
FT                   L-APP isoforms"
FT   DISULFID        38..62
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        73..117
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        98..105
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        133..187
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        144..174
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        158..186
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        291..341
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   DISULFID        300..324
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   DISULFID        316..337
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   CROSSLNK        763
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:22847417"
FT   VAR_SEQ         289
FT                   /note="E -> V (in isoform APP695)"
FT                   /evidence="ECO:0000303|PubMed:2900758"
FT                   /id="VSP_000015"
FT   VAR_SEQ         290..364
FT                   /note="Missing (in isoform APP695)"
FT                   /evidence="ECO:0000303|PubMed:2900758"
FT                   /id="VSP_000016"
FT   MUTAGEN         656
FT                   /note="S->A: No chondroitin sulfate linkage to isoform L-
FT                   APP733."
FT                   /evidence="ECO:0000269|PubMed:7737970"
FT   MUTAGEN         704
FT                   /note="G->V: Little oxidized neuronal proteins. Scarce
FT                   amyloid-beta protein 42 aggregation. No neurotoxicity."
FT                   /evidence="ECO:0000269|PubMed:11959460"
FT   MUTAGEN         732..733
FT                   /note="HH->GL,GP: Almost complete loss of binding to GNAO1.
FT                   No inhibition of GTPase activity."
FT                   /evidence="ECO:0000269|PubMed:10024358"
FT   MUTAGEN         743
FT                   /note="T->A: No effect on neurite growth and maturation."
FT                   /evidence="ECO:0000269|PubMed:10341243"
FT   MUTAGEN         743
FT                   /note="T->E: Inhibits neurite growth and maturation."
FT                   /evidence="ECO:0000269|PubMed:10341243"
FT   MUTAGEN         757
FT                   /note="Y->G: No DBB1 binding."
FT                   /evidence="ECO:0000269|PubMed:9930726"
FT   MUTAGEN         759
FT                   /note="N->A: Some DBB1 binding."
FT                   /evidence="ECO:0000269|PubMed:9930726"
FT   MUTAGEN         762
FT                   /note="Y->A: Some DBB1 binding."
FT                   /evidence="ECO:0000269|PubMed:9930726"
FT   MUTAGEN         763
FT                   /note="K->R: Loss of ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:22847417"
FT   TURN            674..676
FT                   /evidence="ECO:0007829|PDB:2LI9"
FT   TURN            679..686
FT                   /evidence="ECO:0007829|PDB:1NMJ"
FT   HELIX           687..695
FT                   /evidence="ECO:0007829|PDB:1NMJ"
SQ   SEQUENCE   770 AA;  86704 MW;  C26C9D6BB2D929A7 CRC64;
     MLPSLALLLL AAWTVRALEV PTDGNAGLLA EPQIAMFCGK LNMHMNVQNG KWESDPSGTK
     TCIGTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHTH IVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDSIDSAD AEEDDSDVWW GGADTDYADG GEDKVVEVAE EEEVADVEEE
     EAEDDEDVED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSVSSQSLL KTTSEPLPQD
     PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPHHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHPFGVDSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFGHDSG FEVRHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
